The commonly used AEDs and the experimental therapies that have been applied in the treatment of Dravet syndrome.
Abstract
In the past decade, hundreds of mutations have been found in the SCN1A (sodium voltage-gated channel α subunit 1) gene in the epileptic patients. The functioning of the SCN1A gene products is intensively studied in the neuroscience field. The loss-of-function mutations of the SCN1A gene are the causative factor of Dravet syndrome, an intractable epilepsy syndrome. With the loss-of-function Nav1.1 (the protein encoded by SCN1A gene), the selective dysfunction of the inhibitory parvalbumin (PV) interneurons impairs the balance of excitatory and inhibitory synaptic inputs to the downstream neurons, and causes the hyperexcitability of the neuronal network. The underlying mechanism is that the axon initial segments (AISs) of inhibitory parvalbumin interneurons predominantly express Nav1.1, particularly in the proximal end of the AISs. The deficiency of Nav1.1 weakens the excitability of the inhibitory parvalbumin neurons and leads to the hyperexcitability of the neuronal network. The sodium channel blockers, one category of the antiepileptic drugs (AEDs) that specifically block the activity of VGSCs, may potentially worsen the defect of Nav1.1 of the PV interneurons in the patients with the SCN1A gene loss-of-function mutations, aggravate the clinical manifestation, and increase the seizure frequency of those patients.
Keywords
- epilepsy
- Dravet syndrome
- voltage-gated sodium channel
- axon initial segment
- interneuron
1. Introduction
Voltage-gated sodium channels (VGSCs) play an essential role in the generation of the action potentials, which are the primary way for the communication between the excitable cells, particularly the neurons. The action potential is the fast method to collect the afferent sensory information and to relay the efferent motor commands in the nervous system. The pathways to transfer the action potentials rely on the organized expression and the proper functioning of VGSCs [1]. The genetic mutations that cause the defected expression of VGSCs or the malfunction of the altered VGSC gene products impair the physiological function of conduction pathway [2], nerve nuclei [3], and cortical neurons [4]. Epilepsy is a common multifactorial neurological disease that is caused by both environmental and genetic factors [5]. Several ion-channel genes are evidently associated with epilepsy, such as
2. VGSC α subunit 1 and Dravet syndrome
Nav1.1 existing in the majority in the brain and was labeled at the soma and dendrites of the neurons in the early studies, referred as Na + channel subtype RI, or Type I Na(+) channel alpha-subunit [11, 12]. Nowadays, more than 1000 mutations [13] have been found in the
Both the haploinsufficiency and the pore-forming mutations of
3. Animal models and pathogenic mechanism of Dravet syndrome
Based on the genotyping results that the
Furthermore, the Ogiwara group in Japan provided the results from an
The other type of
4. Inhibitory interneurons and the features for their specialties
During the processing of the neuronal activities in the central nervous system, the simultaneous excitation and inhibition assure the proper excitability of the neuronal network and the precise control of the neuronal functions. Inhibition in the cortex is generated by the GABAergic neurons, which make up about 20% of the cortical neuronal population. Compared with the pyramidal cells (excitatory neurons), they have the smaller size and much shorter-range projects of the axon to form the local circuit with the nearby neurons and layers [42]. The interneurons could generate the long-lasting currents, the faster reaction to stimuli, and the higher-frequency signal transmission. The inhibition in a neuronal microcircuit could apply at the right millisecond (timing) and with the precise amount (dosing) exactly matching the inhibitory demand [42, 43]. The defects of GABAergic neuronal function have been identified as the contributive factors to the neuronal diseases, such as epilepsy, schizophrenia, and autism spectrum disorders [44, 45]. The cell therapy strategy of the GABAergic neurons for epilepsy was applied in several significant studies of epileptic model and stem cells [44, 46]. In the studies of animal models of Dravet syndrome, the constitutive Na1.1 knockout selectively impacted the functioning of the inhibitory parvalbumin interneurons, spared the detectable dysfunction of the excitatory neurons, and caused by the imbalance of excitation and inhibition, which led to the spontaneous and intractable seizures [4, 38, 39]. On the background of the Nav1.1 knockout specifically in the PV neurons, the addition of Nav1.1 knockout specifically in the excitatory neurons could alleviate the clinical manifestation of Dravet syndrome [6] and potentially re-balance the excitatory and inhibitory neuronal activity. Based on those results, we can understand that the balancing status of inhibitory neurons and excitatory neurons functioning is the determinant of the clinical phenotypes of Drave syndrome.
The several types of inhibitory interneurons are called as “basket” cells, “chandelier” cells, and “Martinotti” cells due to their morphological features. Because of their morphological advantages, they connect and inhibit the particular compartment of principal neurons [42]. The “basket” cells have the highly branched axons that innervate the target somas and the proximal dendrites of pyramidal neurons, as the axonal branches appear like baskets surrounding the pyramidal neurons. In hippocampus CA1, the parvalbumin-expressing basket cells (PVBCs, 26% of CA1 interneurons) are more than the cholecystokinin-expressing basket cells (CCKBCs, 12% of CA1 interneurons) [47]. The PVBCs place 99% output to connect the pyramidal cells and the rest 1% output to form the gap junctions and reciprocal synaptic connections onto themselves or other interneurons generating gamma oscillation [48, 49]. The “chandelier” cells that are also parvalbumin positive have the “cartridges” shape of the axonal arbors that selectively inhibit the AISs of pyramidal cells, and hence they are also called the axon-axonic cells providing precise control of the action potential generation of pyramidal cells [48, 50, 51]. The axon-axonic cells represent about 15% of all PV hippocampal interneurons [47]. The “Martinotti” cells target the apical dendritic tuft and express the somatostatin and calbindin but not parvalbumin or vasoactive intestinal peptide (VIP) [52]. In the hippocampus, the rest of PV cells is “Bistratified” cells, which represent about 25% of PV hippocampal interneurons with the PV-immunosignal on the somatodendritic compartments. In the PVBCs, the Na+ channels are sparse in the dendrites where K+ channels predominate. The Na+ channels cluster at the AIS of PVBCs. In fact, 99% of PVBC Na+ channels are located in the axonal compartment [53]. The unique feature of the high-density distribution of Na+ channels at the PVBC AISs determines the fast-spiking pattern of the PVBCs, which typically generate uniform, non-changing, and high-frequency discharge [54].
5. AIS and VGSC
Axon initial segment (AIS) contains the high density of sodium and potassium channels; the scaffolding protein ankyrin G (AnkG), βIV spectrin, and extracellular matrix–binding protein neurofascin; and the ion channel–associated protein FGF14 (fibroblast growth factor 14). Those are necessary to help the sodium channels locate and cluster at the AIS [55]. The AIS has the lowest threshold for action potential initiation because of the highest density of sodium channels when compared with somatodendritic compartment [53]. The proper functioning of AIS is essential for action potential initiation and adaptive cell excitability of both pyramidal cells (excitatory neurons) and GABAergic interneurons (inhibitory neurons). Many factors regulate the function of the sodium channels at the AIS [55, 56]. First, the distinctive VGSC α subunit types express in specific neuronal types and the particular regions of AIS. In the human brain tissue, the fluorescence signals of Nav1.1 have been found at the thinly AnkG-labeled AIS, which putatively belongs to the interneurons, while Nav1.2 and Nav1.6 are located at the AISs of human cortical pyramidal cells [51]. Nav1.6, the low-threshold sodium channel subtype, accumulates at the distal end of AIS of cortical pyramidal cells, which is responsible for generating the action potentials. The high-threshold Nav1.2 locates at the proximal end of AIS of cortical pyramidal cells, which regulates the action potential backpropagation [57]. The Nav1.1 has been found at the proximal end of AIS of cortical and cerebellar interneurons and the axons of main olfactory bulb neurons. The Nav1.1 immunosignals predominantly outline the axons of the parvalbumin-positive neurons [58]. The action potential threshold of Nav1.6 is more hyperpolarized (15–25 mV lower) than that of both Nav1.2 and Nav1.1. Unlike Nav1.6 more likely producing a persistent current, Nav1.1 and Nav1.2 show the apparent use-dependent inactivation (higher than 20 Hz) [59, 60]. Therefore, the accumulated Nav1.6 at the distal end of the AIS facilitates the action potential initiation, while Nav1.2 and Nav1.1 subunits gathering at the proximal end of AIS prevent the high-frequency firing of nerve cells backward.
Second, the molecule complex at AIS, composed of the ion channels (Kv1, T-type Ca2+ channel) and ligands (FGF14, VGSC β subunit 1, and βIV spectrin), directly or indirectly cooperates with Na+ channel and regulates the neuronal excitability. FGF14 could directly interact with the C-terminal of VGSC α subunit (Nav1.1, Nav1.2, Nav1.6) in the transfected HEK293 cells [61]. The
Third, the location and the size of the AIS can be adapted for the neuronal activity and the long-term plasticity. The longer AIS, the higher excitability of the neuron. The more proximal location of the AIS, the higher excitability of the neuron. The chronic depolarization of the dissociated neurons moved the AIS distally and then decreased the neuronal excitability. The dynamic regulation of the AIS location through activity-dependent structural reorganization relied on the activation of T-type voltage-gated calcium channels and the elevation of intracellular [Ca2+] [67]. On the other hand, the experiments to eliminate the sensory stimuli made the AIS longer with little change in Na+ channel density and ion channel composition at the AIS, which increased the whole cell Na+ current, and the neuronal excitability. However, those adaptive responses also depend on the neuronal types due to the distinctions of the AIS location of different neurons under the standard conditions [67]. In the PV interneurons, the action potentials are generated at 20 μm away from the soma at the AIS [53], which means the proximal part of the AIS of the PV neurons locates even closer than 20 μm since the action potential generates at the beginning of the distal part of the AIS. The AIS of the PV neurons locates more proximal than the AIS of pyramidal cells that has been observed at 20–60 μm from the soma by ankyrin G staining [68]. Using specific neuronal marker labeling, Höfflin et al. saw the AISs of the pyramidal neurons were significantly longer than that of the interneurons [69]. Based on those findings of the PV interneurons and their AISs, neuroscientists may have many interests in the regulatory mechanisms of Nav1.1 cooperative functioning and adaptive response to the neuronal activity, coupling with the dynamic plasticity of the PV interneuron AIS.
With the specialized output structures of PV interneurons (“basket” or “chandelier cartridge”), the interactions of the PV interneurons (PVBCs or chandelier cells) and the pyramidal cells, inhibitory synapses, are accordingly subject to the dynamic regulation of adaptive neuronal functioning and the AIS plasticity. The chandelier cell axon terminals only contact the AISs of pyramidal cells and have three to five boutons per cartridge. The innervation patterns are similar at different postnatal age. Multiple chandelier cells (four at estimate) connect one pyramidal cell, while one chandelier cell contacts 35–50% of pyramidal cells in the traversed area by its axonal arbor [70]. The inhibitory synapses exist in the innervation of a chandelier cell to the pyramidal cell by nature. The innervation could be visible by labeling the chandelier cells (pre-synaptic component) with the marker of GABA membrane transporter 1 (GAT1) or parvalbumin (PV) and labeling the post-synaptic pyramidal cell AIS with GABAA receptor α2 subunit. The structures and functioning status of those synapses keep updated to meet the dynamic developmental demands [71, 72] and are impacted in the specific areas by pathological conditions, such as epilepsy and schizophrenia [73, 74].
6. Treatment to Dravet syndrome and therapeutic response
Dravet syndrome is an intractable epileptic encephalopathy with the unfavorable outcome. The most commonly used AEDs for patients with Dravet syndrome include valproate, topiramate, benzodiazepines, stiripentol, and potassium bromide [22]. Because the high percentage of patients with Dravet syndrome have the
Valproate is the most frequently used AED to treat Dravet syndrome. Shi et al. found that 87% of
7. Discussion
Epilepsy is a chronic neurological disease worldwide, which jeopardizes the patients’ lives, burdens the patients’ family and caregivers, and requires to be concerned with the increasing attention to the affordable therapies, the effectiveness of current treatment strategies, and the social support to the patients and the caregivers. The pharmaceutical therapy (the application of AEDs) is the most commonly used strategy to fight against epilepsy. However, 30% of epilepsy patients are resistant to the optimized AED treatment without obvious precipitating factors [95]. Dravet syndrome might be an intractable and adverse form of extremity, which requires the multiple AED remedy (Table 1) and resistant to many AEDs over time [22]. The two major mechanisms are responsible for the resistance to AEDs in chronic epilepsy. One is the desensitization or modification of the molecular targets of AEDs during the chronic pathological process (frequent and recurring seizures), and the other is the overexpression of multidrug transporters, such as P-glycoprotein [96]. The sodium channel blocker is one of the main classes of AEDs. The genetic polymorphisms of the molecular targets, VGSC α subunits, are significantly associated with AED resistance. The genetic variant of
Agent or medication | Main action for treatment | Dosage in the treatment | Responder rate (>50% reduction) | Retain period (year) | Retain combination remedy | Aggravation rate (>25% increase) | Cause of death (SE or SUDEP*) |
---|---|---|---|---|---|---|---|
Valproate (VPA) | Na+ Ca+ channel ↓ GABA ↑ GLUT ↑ [91] | 30–50 mg/kg/d [92] | 52 and 41% [76] | VPA + Br VPA + CZP + Br VPA + CLB + Br [81] | SUDEP [92] | ||
Topiramate (TPM) | Na+ Ca+ channel ↓ GABA ↑ GLUT ↑ [91] | 7.5–15 mg/kg/d [92] | 57 and 33% [76] | 17% [82] | |||
Clobazam (CLB) | GABA ↑ [91] | 0.2–1 mg/kg/d [92] | 44 and 48% [76] | VPA + Br VPA + CLB + Br [81] | SUDEP [92] | ||
Clonazepam (CZP) | GABA ↑ [91] | 0.03–0.1 mg/kg/d [92] | 44 and 38% [76] | VPA + Br VPA + CZP + Br [81] | |||
Zonisamide (ZNS) | Na+ Ca+ channel ↓ [91] | 36 and 38% [76] | 44% [82] | ||||
Phenobarbital (PHB) | GABA ↑ [91] | 29 and 35% [76] | |||||
Phenytoin (PHT) | Sodium channel blocker [91] | 10 and 29% [76] | 50% [82] | ||||
Stiripentol (STP) | GABAergic enhancer [93] | 35–50 mg/kg/d [85] | 23% [86] | 5 [86] | VPA + CLB CLB + TPM VPA + TPM [86] | 23% [86] 6% [82] | |
Bromide (Br) | Stabilize the excitable membrane through hyperpolarization [94] | 30–70 mg/kg/d [76] 30–106 mg/kg/d [82] | 71 and 94% [76] 81% [82] | 2.5 [76] 2 [82] | VPA + Br VPA + CZP + Br VPA + CLB + Br [76] VPA + TPM + CLB [82] | ||
Levetiracetam (LEV) | Act as a neuromodulator | 50–60 mg/kg/d [84] | 44–64% [84] | VPA + TPM + LEV [84] VPA + CLB + LEV [84] | 5% [82] | ||
Lamotrigine (LTG) | Sodium channel blocker [91] | 2.5–12.5mg/kg/d [75] | 5% (1/21) [75] | 14 m# [75] | VPA + CZP + CLB [75] | 57% [82] 80% [75] | SUDEP [92] |
Carbamazepine (CBZ) | Sodium channel blocker [91] | 200–900 mg/day [81] | 9% [76] | 0.9–>20 [81] | VPA CLB STP ZNS LEV CLN TPM PHT [81] | 33% [81] 71% [82] 21% [76] | SUDEP, SE [81] |
Oxcarbazepine (OXC) | Sodium channel blocker [91] | 600–1200 mg/day [81] | Withdrawal + complete stop | 0.1–>20 [81] | VPA CBZ ZNS LEV CLN PHB [81] | 72% [82] | SUDEP [81] |
Verapamil | Voltage-gated calcium channel blocker [83] | 1.5 mg/kg/d [83] | 2/2 [83] | 13–>20 m# | VPA TPM PHT ETS† [83] | ||
Clemizole | H1 antagonist [88] | 100 μM swim bath (zebrafish) | Significant reduce seizure behavior | Single dose | Monotherapy [88] | ||
Methylphenidate | Increase dopamine release (rat) [89] | 0.5–2.0 mg/kg i.p. [89] | Significant improvement | Single dose | Monotherapy [89] |
8. Conclusions
Dravet syndrome, an intractable epilepsy syndrome, affects the initially normal infants with febrile or non-febrile seizures, myoclonic seizures, hemiclonic seizures, and developmental delay. The
Acknowledgments
The author greatly appreciates the financial support from Postdoctoral Startup Research Foundation of Guangzhou Human Resource Department (310109-011).
References
- 1.
Kruger LC, Isom LL. Voltage-gated Na+ channels: Not just for conduction. Cold Spring Harbor Perspectives in Biology. 2016; 8 (6). pii: a029264. DOI: 10.1101/cshperspect.a029264 - 2.
Hoeijmakers JG, Faber CG, Lauria G, Merkies IS, Waxman SG. Small-fibre neuropathies—Advances in diagnosis, pathophysiology and management. Nature Reviews. Neurology. 2012; 8 (7):369-379. DOI: 10.1038/nrneurol.2012.97 - 3.
Chen K, Godfrey DA, Ilyas O, Xu J, Preston TW. Cerebellum-related characteristics of Scn8a-mutant mice. Cerebellum. 2009; 8 (3):192-201. DOI: 10.1007/s12311-009-0110-z. Epub 2009 May 8 - 4.
Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, Burton KA, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nature Neuroscience. 2006; 9 (9):1142-1149. Epub 2006 Aug 20 - 5.
Ferraro TN, Dlugos DJ, Buono RJ. Role of genetics in the diagnosis and treatment of epilepsy. Expert Review of Neurotherapeutics. 2006; 6 (12):1789-1800 - 6.
Ogiwara I, Iwasato T, Miyamoto H, Iwata R, Yamagata T, Mazaki E, et al. Nav1.1 haploinsufficiency in excitatory neurons ameliorates seizure-associated sudden death in a mouse model of Dravet syndrome. Human Molecular Genetics. 2013; 22 (23):4784-4804. DOI: 10.1093/hmg/ddt331. Epub 2013 Aug 6 - 7.
Shi X, Yasumoto S, Kurahashi H, Nakagawa E, Fukasawa T, Uchiya S, Hirose S. Clinical spectrum of SCN2A mutations. Brain & Development. 2012 Aug; 34 (7):541-545. DOI: 10.1016/j.braindev.2011.09.016. Epub 2011 Oct 24 - 8.
Wagnon JL, Meisler MH. Recurrent and non-recurrent mutations of SCN8A in epileptic encephalopathy. Frontiers in Neurology. 2015 May; 6 :104. DOI: 10.3389/fneur.2015.00104. eCollection 2015 - 9.
Hirose S. Mutant GABA(A) receptor subunits in genetic (idiopathic) epilepsy. Progress in Brain Research. 2014; 213 :55-85. DOI: 10.1016/B978-0-444-63326-2.00003-X - 10.
Syrbe S, Hedrich UBS, Riesch E, Djémié T, Müller S, Møller RS, et al. De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy. Nature Genetics. 2015 Apr; 47 (4):393-399. DOI: 10.1038/ng.3239. Epub 2015 Mar 9 - 11.
Westenbroek RE, Merrick DK, Catterall WA. Differential subcellular localization of the RI and RII Na+ channel subtypes in central neurons. Neuron. 1989 Dec; 3 (6):695-704 - 12.
Gong B, Rhodes KJ, Bekele-Arcuri Z, Trimmer JS. Type I and type II Na(+) channel alpha-subunit polypeptides exhibit distinct spatial and temporal patterning, and association with auxiliary subunits in rat brain. The Journal of Comparative Neurology. 1999 Sep; 412 (2):342-352 - 13.
Meng H, Xu HQ, Yu L, Lin GW, He N, Su T, et al. The SCN1A mutation database: Updating information and analysis of the relationships among genotype, functional alteration, and phenotype. Human Mutation. 2015 Jun; 36 (6):573-580. DOI: 10.1002/humu.22782. Epub 2015 Apr 13 - 14.
Escayg A, MacDonald BT, Meisler MH, Baulac S, Huberfeld G, An-Gourfinkel I, Malafosse A. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nature Genetics. 2000; 24 :343-345 - 15.
Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. American Journal of Human Genetics. 2001 Jun; 68 (6):1327-1332. Epub 2001 May 15 - 16.
Weller CM, Pelzer N, de Vries B, López MA, De Fàbregues O, Pascual J, et al. Two novel SCN1A mutations identified in families with familial hemiplegic migraine. Cephalalgia. 2014 Nov; 34 (13):1062-1069. DOI: 10.1177/0333102414529195 - 17.
Cheah CS, Yu FH, Westenbroek RE, Kalume FK, Oakley JC, Potter GB, et al. Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2012 Sep; 109 (36):14646-14651. DOI: 10.1073/pnas.1211591109. Epub 2012 Aug 20 - 18.
Miller IO, Sotero de Menezes MA. SCN1A-related seizure disorders. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, Editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. 2007 Nov 29 [Updated 2014 May 15] - 19.
Wu YW, Sullivan J, McDaniel SS, Meisler MH, Walsh EM, Li SX, Kuzniewicz MW. Incidence of Dravet Syndrome in a US Population. Pediatrics. 2015 Nov; 136 (5):e1310-e1315. DOI: 10.1542/peds.2015-1807. Epub 2015 Oct 5 - 20.
Gataullina S, Dulac O. From genotype to phenotype in Dravet disease. Seizure. 2017 Jan; 44 :58-64. DOI: 10.1016/j.seizure.2016.10.014. Epub 2016 Oct 21. Review - 21.
Dravet C. Dravet syndrome history. Developmental Medicine and Child Neurology. 2011 Apr; 53 (Suppl 2):1-6. DOI: 10.1111/j.1469-8749.2011.03964.x - 22.
Dravet C, Oguni H. Dravet syndrome (severe myoclonic epilepsy in infancy). Handbook of Clinical Neurology. 2013; 111 :627-633. DOI: 10.1016/B978-0-444-52891-9.00065-8 - 23.
Ishii A, Watkins JC, Chen D, Hirose S, Hammer MF. Clinical implications of SCN1A missense and truncation variants in a large Japanese cohort with Dravet syndrome. Epilepsia. 2017 Feb; 58 (2):282-290. DOI: 10.1111/epi.13639. Epub 2016 Dec 24 - 24.
Bechi G, Scalmani P, Schiavon E, Rusconi R, Franceschetti S, Mantegazza M. Pure haploinsufficiency for Dravet syndrome Na(V)1.1 (SCN1A) sodium channel truncating mutations. Epilepsia. 2012 Jan; 53 (1):87-100. DOI: 10.1111/j.1528-1167.2011.03346.x. Epub 2011 Dec 9 - 25.
Kamiya K, Kaneda M, Sugawara T, Mazaki E, Okamura N, Montal M, et al. A nonsense mutation of the sodium channel gene SCN2A in a patient with intractable epilepsy and mental decline. The Journal of Neuroscience. 2004; 24 :2690-2698 - 26.
McArdle EJ, Kunic JD, George AL Jr. Novel SCN1A frameshift mutation with absence of truncated Nav1.1 protein in severe myoclonicepilepsy of infancy. American Journal of Medical Genetics. Part A. 2008 Sep; 146A (18):2421-2423. DOI: 10.1002/ajmg.a.32448 - 27.
Marini C, Scheffer IE, Nabbout R, Suls A, De Jonghe P, Zara F, Guerrini R. The genetics of Dravet syndrome. Epilepsia. 2011 Apr; 52 (Suppl 2):24-29. DOI: 10.1111/j.1528-1167.2011.02997.x - 28.
Hilber K, Sandtner W, Kudlacek O, Glaaser IW, Weisz E, Kyle JW, et al. The selectivity filter of the voltage-gated sodium channel is involved in channel activation. The Journal of Biological Chemistry. 2001 Jul; 276 (30):27831-27839. Epub 2001 May 29 - 29.
Ohno Y, Ishihara S, Mashimo T, Sofue N, Shimizu S, Imaoku T, et al. Scn1a missense mutation causes limbic hyperexcitability and vulnerability to experimental febrile seizures. Neurobiology of Disease. 2011 Feb; 41 (2):261-269. DOI: 10.1016/j.nbd.2010.09.013. Epub 2010 Sep 25 - 30.
Mashimo T, Ohmori I, Ouchida M, Ohno Y, Tsurumi T, Miki T, et al. A missense mutation of the gene encoding voltage-dependent sodium channel (Nav1.1) confers susceptibility to febrile seizures in rats. The Journal of Neuroscience. 2010 Apr; 30 (16):5744-5753. DOI: 10.1523/JNEUROSCI.3360-09.2010 - 31.
Meadows L, Malhotra JD, Stetzer A, Isom LL, Ragsdale DS. The intracellular segment of the sodium channel beta 1 subunit is required for its efficient association with the channel α subunit. Journal of Neurochemistry. 2001; 76 (6):1871-1878 - 32.
Yamagishi T, Li RA, Hsu K, Marbán E, Tomaselli GF. Molecular architecture of the voltage-dependent Na channel: Functional evidence for alpha helices in the pore. The Journal of General Physiology. 2001 Aug; 118 (2):171-182 - 33.
Mantegazza M, Catterall WA. Voltage-gated Na+ channels: Structure, function, and pathophysiology. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, Editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th ed. Bethesda (MD): National Center for Biotechnology Information (US); 2012 - 34.
Tsukamoto T, Chiba Y, Wakamori M, Yamada T, Tsunogae S, Cho Y, et al. Differential binding of tetrodotoxin and its derivatives to voltage-sensitive sodium channel subtypes (Nav 1.1 to Nav 1.7). British Journal of Pharmacology. 2017; 174 (21):3881-3892. DOI: 10.1111/bph.13985. Epub 2017 Sep 20 - 35.
Onwuli DO, Beltran-Alvarez P. An update on transcriptional and post-translational regulation of brain voltage-gated sodium channels. Amino Acids. 2016 Mar; 48 (3):641-651. DOI: 10.1007/s00726-015-2122-y. Epub 2015 Oct 27 - 36.
Patel RR, Barbosa C, Xiao Y, Cummins TR. Human Nav1.6 channels generate larger resurgent currents than human Nav1.1 channels, but the Navbeta4 peptide does not protect either isoform from use-dependent reduction. PLoS One. 2015 Jul; 10 (7):e0133485. DOI: 10.1371/journal.pone.0133485. eCollection 2015 - 37.
Kaneko Y, Watanabe S. Expression of Nav1.1 in rat retinal AII amacrine cells. Neuroscience Letters. 2007 Sep; 424 (2):83-88. Epub 2007 Aug 1 - 38.
Mistry AM, Thompson CH, Miller AR, Vanoye CG, George AL Jr, Kearney JA. Strain- and age-dependent hippocampal neuron sodium currents correlate with epilepsy severity in Dravet syndrome mice. Neurobiology of Disease. 2014 May; 65 :1-11. DOI: 10.1016/j.nbd.2014.01.006. Epub 2014 Jan 14 - 39.
Ogiwara I, Miyamoto H, Morita N, Atapour N, Mazaki E, Inoue I, et al. Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: A circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. The Journal of Neuroscience. 2007 May; 27 (22):5903-5914 - 40.
De Stasi AM, Farisello P, Marcon I, Cavallari S, Forli A, Vecchia D, et al. Unaltered network activity and Interneuronal firing during spontaneous cortical dynamics in vivo in a mouse model of severe myoclonic epilepsy of infancy. Cerebral Cortex. 2016 Apr; 26 (4):1778-1794. DOI: 10.1093/cercor/bhw002. Epub 2016 Jan 26 - 41.
Tang B, Dutt K, Papale L, Rusconi R, Shankar A, Hunter J, et al. A BAC transgenic mouse model reveals neuron subtype-specific effects of a generalized epilepsy with febrile seizures plus (GEFS+) mutation. Neurobiology of Disease. 2009 Jul; 35 (1):91-102. DOI: 10.1016/j.nbd.2009.04.007. Epub 2009 May 3 - 42.
Isaacson JS, Scanziani M. How inhibition shapes cortical activity. Neuron. 2011 Oct; 72 (2):231-243. DOI: 10.1016/j.neuron.2011.09.027 - 43.
Markram H, Toledo-Rodriguez M, Wang Y, Gupta A, Silberberg G, Wu C. Interneurons of the neocortical inhibitory system. Nature Reviews. Neuroscience. 2004 Oct; 5 (10):793-807 - 44.
Hunt RF, Baraban SC. Interneuron transplantation as a treatment for epilepsy. Cold Spring Harbor Perspectives in Medicine. 2015 Dec; 5 (12):pii: a022376 - 45.
Shetty AK, Upadhya D. GABA-ergic cell therapy for epilepsy: Advances, limitations and challenges. Neuroscience and Biobehavioral Reviews. 2016 Mar; 62 :35-47. DOI: 10.1016/j.neubiorev.2015.12.014 - 46.
DeRosa BA, Belle KC, Thomas BJ, Cukier HN, Pericak-Vance MA, Vance JM, Dykxhoorn DM. hVGAT-mCherry:A novel molecular tool for analysis of GABAergic neurons derived from human pluripotent stem cells. Molecular and Cellular Neurosciences. 2015 Sep; 68 :244-257. DOI: 10.1016/j.mcn.2015.08.007 - 47.
Bezaire MJ, Soltesz I. Quantitative assessment of CA1 local circuits: Knowledge base for interneuron-pyramidal cell connectivity. Hippocampus. 2013 Sep; 23 (9):751-785. DOI: 10.1002/hipo.22141. Epub 2013 Jul 10 - 48.
Baude A, Bleasdale C, Dalezios Y, Somogyi P, Klausberger T. Immunoreactivity for the GABAA receptor alpha1 subunit, somatostatin and Connexin 36 distinguishes axoaxonic, basket, and bistratified interneurons of the rat hippocampus. Cerebral Cortex. 2007 Sep; 17 (9):2094-2107. Epub 2006 Nov 22 - 49.
Pawelzik H, Hughes DI, Thomson AM. Modulation of inhibitory autapses and synapses on rat CA1 interneurones by GABA(A) receptor ligands. The Journal of Physiology. 2003 Feb; 546 (Pt 3):701-716 - 50.
Somogyi P, Nunzi MG, Gorio A, Smith AD. A new type of specific interneuron in the monkey hippocampus forming synapses exclusively with the axon initial segments of pyramidal cells. Brain Research. 1983 Jan; 259 (1):137-142 - 51.
Tian C, Wang K, Ke W, Guo H, Shu Y. Molecular identity of axonal sodium channels in human cortical pyramidal cells. Frontiers in Cellular Neuroscience. 2014 Sep; 8 :297. DOI: 10.3389/fncel.2014.00297. eCollection 2014 - 52.
Sugino K, Hempel CM, Miller MN, Hattox AM, Shapiro P, Wu C, et al. Molecular taxonomy of major neuronal classes in the adult mouse forebrain. Nature Neuroscience. 2006 Jan; 9 (1):99-107. Epub 2005 Dec 20 - 53.
Hu H, Jonas P. A supercritical density of Na(+) channels ensures fast signaling in GABAergic interneuron axons. Nature Neuroscience. 2014 May; 17 (5):686-693. DOI: 10.1038/nn.3678. Epub 2014 Mar 23 - 54.
Li T, Tian C, Scalmani P, Frassoni C, Mantegazza M, Wang Y, et al. Action potential initiation in neocortical inhibitory interneurons. PLoS Biology. 2014; 12 (9):e1001944. DOI: 10.1371/journal.pbio.1001944. eCollection 2014 Sep - 55.
Grubb MS, Burrone J. Activity-dependent relocation of the axon initial segment fine-tunes neuronal excitability. Nature. 2010 Jun; 465 (7301):1070-1074. DOI: 10.1038/nature09160. Epub 2010 Jun 13 - 56.
Grubb MS, Shu Y, Kuba H, Rasband MN, Wimmer VC, Bender KJ. Short- and long-term plasticity at the axon initial segment. The Journal of Neuroscience. 2011 Nov; 31 (45):16049-16055. DOI: 10.1523/JNEUROSCI.4064-11.2011 - 57.
Hu W, Tian C, Li T, Yang M, Hou H, Shu Y. Distinct contributions of Na(v)1.6 and Na(v)1.2 in action potential initiation and backpropagation. Nature Neuroscience. 2009 Aug; 12 (8):996-1002. DOI: 10.1038/nn.2359. Epub 2009 Jul 26 - 58.
Lorincz A, Nusser Z. Cell-type-dependent molecular composition of the axon initial segment. The Journal of Neuroscience. 2008 Dec; 28 (53):14329-14340. DOI: 10.1523/JNEUROSCI.4833-08.2008 - 59.
Rush AM, Dib-Hajj SD, Waxman SG. Electrophysiological properties of two axonal sodium channels, Nav1.2 and Nav1.6, expressed in mouse spinal sensory neurones. The Journal of Physiology. 2005 May; 564 (Pt 3):803-815. Epub 2005 Mar 10 - 60.
Spampanato J, Escayg A, Meisler MH, Goldin AL. Functional effects of two voltage-gated sodium channel mutations that cause generalized epilepsy with febrile seizures plus type 2. The Journal of Neuroscience. 2001 Oct; 21 (19):7481-7490 - 61.
Laezza F, Lampert A, Kozel MA, Gerber BR, Rush AM, Nerbonne JM, et al. FGF14 N-terminal splice variants differentially modulate Nav1.2 and Nav1.6-encoded sodiumchannels. Molecular and Cellular Neurosciences. 2009 Oct; 42 (2):90-101. DOI: 10.1016/j.mcn.2009.05.007. Epub 2009 May 22 - 62.
Alshammari TK, Alshammari MA, Nenov MN, Hoxha E, Cambiaghi M, Marcinno A, et al. Genetic deletion of fibroblast growth factor 14 recapitulates phenotypic alterations underlying cognitive impairment associated with schizophrenia. Translational Psychiatry. 2016 May; 6 :e806. doi: 10.1038/tp.2016.66 - 63.
Goetz R, Dover K, Laezza F, Shtraizent N, Huang X, Tchetchik D, et al. Crystal structure of a fibroblast growth factor homologous factor (FHF) defines a conserved surface on FHFs for binding and modulation of voltage-gated sodium channels. The Journal of Biological Chemistry. 2009; 284 (26):17883-17896. DOI: 10.1074/jbc.M109.001842. Epub 2009 Apr 30 - 64.
Shavkunov A1, Panova N, Prasai A, Veselenak R, Bourne N, Stoilova-McPhie S, Laezza F. Bioluminescence methodology for the detection of protein-protein interactions within the voltage-gated sodium channel macromolecular complex. ASSAY and Drug Development Technologies. 2012 Apr; 10 (2):148-60. doi: 10.1089/adt.2011.413. Epub 2012 Feb 24 - 65.
Jones SL, Svitkina TM. Axon initial segment cytoskeleton: Architecture, development, and role in neuron polarity. Neural Plasticity. 2016; 2016 :6808293. DOI: 10.1155/2016/6808293. Epub 2016 Jul 17 - 66.
Brackenbury WJ, Calhoun JD, Chen C, Miyazaki H, Nukina N, Oyama F, et al. Functional reciprocity between Na+ channel Nav1.6 and beta1 subunits in the coordinated regulation of excitability and neurite outgrowth. Proceedings of the National Academy of Sciences of the United States of America. 2010 Feb; 107 (5):2283-2288. DOI: 10.1073/pnas.0909434107. Epub 2010 Jan 19 - 67.
Kuba H, Oichi Y, Ohmori H. Presynaptic activity regulates Na(+) channel distribution at the axon initial segment. Nature. 2010 Jun; 465 (7301):1075-1078. DOI: 10.1038/nature09087. Epub 2010 Jun 13 - 68.
Wefelmeyer W, Cattaert D, Burrone J. Activity-dependent mismatch between axo-axonic synapses and the axon initial segment controls neuronal output. Proceedings of the National Academy of Sciences of the United States of America. 2015 Aug; 112 (31):9757-9762. DOI: 10.1073/pnas.1502902112. Epub 2015 Jul 20 - 69.
Höfflin F, Jack A, Riedel C, Mack-Bucher J, Roos J, Corcelli C, et al. Heterogeneity of the axon initial segment in interneurons and pyramidal cells of rodent visual cortex. Frontiers in Cellular Neuroscience. 2017 Nov; 11 :332. DOI: 10.3389/fncel.2017.00332. eCollection 2017 - 70.
Inan M, Blázquez-Llorca L, Merchán-Pérez A, Anderson SA, DeFelipe J, Yuste R. Dense and overlapping innervation of pyramidal neurons by chandelier cells. The Journal of Neuroscience. 2013 Jan; 33 (5):1907-1914. DOI: 10.1523/JNEUROSCI.4049-12.2013 - 71.
Cruz DA, Eggan SM, Lewis DA. Postnatal development of pre- and postsynaptic GABA markers at chandelier cell connections with pyramidal neurons in monkey prefrontal cortex. The Journal of Comparative Neurology. 2003 Oct; 465 (3):385-400 - 72.
Hardwick C, French SJ, Southam E, Totterdell S. A comparison of possible markers for chandelier cartridges in rat medial prefrontal cortex and hippocampus. Brain Research. 2005 Jan; 1031 (2):238-244 - 73.
Bloomfield C, French SJ, Jones DN, Reavill C, Southam E, Cilia J, Totterdell S. Chandelier cartridges in the prefrontal cortex are reduced in isolation reared rats. Synapse. 2008 Aug; 62 (8):628-631. DOI: 10.1002/syn.20521 - 74.
Pierri JN, Chaudry AS, Woo TU, Lewis DA. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. The American Journal of Psychiatry. 1999 Nov; 156 (11):1709-1719 - 75.
Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998 May; 39 (5):508-512 - 76.
Shi XY, Tomonoh Y, Wang WZ, Ishii A, Higurashi N, Kurahashi H, et al. Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes. Brain & Development. 2016 Jan; 38 (1):40-46. DOI: 10.1016/j.braindev.2015.06.008. Epub 2015 Jul 13 - 77.
Hirose S, Scheffer IE, Marini C, De Jonghe P, Andermann E, Goldman AM, et al. SCN1A testing for epilepsy: Application in clinical practice. Epilepsia. 2013 May; 54 (5):946-952. DOI: 10.1111/epi.12168. Epub 2013 Apr 15 - 78.
Hattori J, Ouchida M, Ono J, Miyake S, Maniwa S, Mimaki N, et al. A screening test for the prediction of Dravet syndrome before one year of age. Epilepsia. 2008 Apr; 49 (4):626-633. Epub 2007 Dec 11 - 79.
Stenhouse SA, Ellis R, Zuberi S. SCN1A genetic test for Dravet Syndrome (severe myoclonic epilepsy of infancy and its clinical subtypes) for use in the diagnosis, prognosis, treatment and management of Dravet syndrome. PLOS Currents. 2013; 5 . pii: ecurrents.eogt.c553b83d745dd79bfb61eaf35e522b0b. DOI: 10.1371/currents.eogt.c553b83d745dd79bfb61eaf35e522b0b - 80.
Connolly MB. Dravet syndrome: Diagnosis and long-term course. The Canadian Journal of Neurological Sciences. 2016 Jun; 43 (Suppl 3):S3-S8. DOI: 10.1017/cjn.2016.243 - 81.
Snoeijen-Schouwenaars FM, Veendrick MJ, an Mierlo P, van Erp G, de Louw AJ, Kleine BU, et al. Carbamazepine and oxcarbazepine in adult patients with Dravet syndrome: Friend or foe? Seizure 2015 Jul; 29 :114-118. DOI: 10.1016/j.seizure.2015.03.010. Epub 2015 Apr 13 - 82.
Lotte J, Haberlandt E, Neubauer B, Staudt M, Kluger GJ. Bromide in patients with SCN1A-mutations manifesting as Dravet syndrome. Neuropediatrics. 2012 Feb; 43 (1):17-21. DOI: 10.1055/s-0032-1307454. Epub 2012 Mar 19 - 83.
Iannetti P, Parisi P, Spalice A, Ruggieri M, Zara F. Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Research. 2009 Jul; 85 (1):89-95. DOI: 10.1016/j.eplepsyres.2009.02.014. Epub 2009 Mar 20 - 84.
Striano P, Coppola A, Pezzella M, Ciampa C, Specchio N, Ragona F, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007 Jul; 69 (3):250-254 - 85.
De Liso P, Chemaly N, Laschet J, Barnerias C, Hully M, Leunen D, et al. Patients with Dravet syndrome in the era of stiripentol: A French cohort cross-sectional study. Epilepsy Research 2016 Sep; 125 :42-46. doi: 10.1016/j.eplepsyres.2016.05.012. Epub 2016 May 28 - 86.
Balestrini S, Sisodiya SM. Audit of use of stiripentol in adults with Dravet syndrome. Acta Neurologica Scandinavica. 2017 Jan; 135 (1):73-79. DOI: 10.1111/ane.12611. Epub 2016 May 27 - 87.
Fulton SP, Van Poppel K, McGregor AL, Mudigoudar B, Wheless JW. Vagus nerve stimulation in intractable epilepsy associated with SCN1A gene abnormalities. Journal of Child Neurology. 2017 Apr; 32 (5):494-498. DOI: 10.1177/0883073816687221. Epub 2017 Jan 12 - 88.
Baraban SC, Dinday MT, Hortopan GA. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nature Communications. 2013; 4 :2410. DOI: 10.1038/ncomms3410 - 89.
Ohmori I, Kawakami N, Liu S, Wang H, Miyazaki I, Asanuma M, et al. Methylphenidate improves learning impairments and hyperthermia-induced seizures caused by an Scn1a mutation. Epilepsia. 2014 Oct; 55 (10):1558-1567. DOI: 10.1111/epi.12750 - 90.
Hayashi K, Ueshima S, Ouchida M, Mashimo T, Nishiki T, Sendo T, et al. Therapy for hyperthermia-induced seizures in Scn1a mutant rats. Epilepsia. 2011 May; 52 (5):1010-1017. DOI: 10.1111/j.1528-1167.2011.03046.x - 91.
Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacology & Therapeutics. 2001 Apr; 90 (1):21-34 - 92.
Ceulemans B, Boel M, Claes L, Dom L, Willekens H, Thiry P, Lagae L. Severe myoclonic epilepsy in infancy: Toward an optimal treatment. Journal of Child Neurology. 2004 Jul; 19 (7):516-521 - 93.
Trojnar MK, Wojtal K, Trojnar MP, Czuczwar SJ. Stiripentol. A novel antiepileptic drug. Pharmacological Reports. 2005 Mar-Apr; 57 (2):154-160 - 94.
Ryan M, Baumann RJ. Use and monitoring of bromides in epilepsy treatment. Pediatric Neurology. 1999 Aug; 21 (2):523-528 - 95.
Kwan P, Brodie MJ. Early identification of refractory epilepsy. The New England Journal of Medicine. 2000 Feb; 342 (5):314-319 - 96.
Wang GX, Wang DW, Liu Y, Ma YH. Intractable epilepsy and the P-glycoprotein hypothesis. The International Journal of Neuroscience. 2016; 126 (5):385-392. DOI: 10.3109/00207454.2015.1038710. Epub 2015 Jul 2 - 97.
Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW, Lui CH, Sin NC, Wong KS, Baum L. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: Correlation among phenotype, genotype, and mRNA expression. Pharmacogenetics and Genomics. 2008 Nov; 18 (11):989-998. DOI: 10.1097/FPC.0b013e3283117d67 - 98.
Lv N, Qu J, Long H, Zhou L, Cao Y, Long L, Liu Z, Xiao B. Association study between polymorphisms in the CACNA1A, CACNA1C, and CACNA1H genes and drug-resistant epilepsy in the Chinese Han population. Seizure. 2015 Aug; 30 :64-69. DOI: 10.1016/j.seizure.2015.05.013. Epub 2015 May 28 - 99.
Huberfeld G, Wittner L, Clemenceau S, Baulac M, Kaila K, Miles R, Rivera C. Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. The Journal of Neuroscience. 2007 Sep; 27 (37):9866-9873 - 100.
Lachos J, Zattoni M, Wieser HG, Fritschy JM, Langmann T, Schmitz G, et al. Characterization of the gene expression profile of human hippocampus in mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsy Research and Treatment. 2011; 2011 :758407. DOI: 10.1155/2011/758407. Epub 2011 Mar 6